References
- Ministero della Salute. Guida alle controindicazioni alle vaccinazioni [accessed 2022 Dec 11] https://www.salute.gov.it/imgs/C_17_pubblicazioni_2759_allegato.pdf
- European Centre for Disease Prevention and Control. Autochthonous transmission of dengue virus in mainland EU/EEA, 2010-present. https://www.ecdc.europa.eu/en/all-topics-z/dengue/surveillance-and-disease-data/autochthonous-transmission-dengue-virus-eueea
- Ripabelli G, Sammarco ML, D’Amico A, De Dona R, Iafigliola M, Parente A, Samprati N, Santagata A, Adesso C, Natale A, et al. Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: results from an active pharmacovigilance study in central Italy. Hum Vaccin Immunother. 2022;18(6):2126668. doi:10.1080/21645515.2022.2126668.
- Ripabelli G, Tamburro M, Buccieri N, Adesso C, Caggiano V, Cannizzaro F, Di Palma MA, Mantuano G, Montemitro VG, Natale A, et al. Active surveillance of adverse events in healthcare workers recipients after vaccination with COVID-19 BNT162b2 vaccine (Pfizer-BioNtech, Comirnaty): a cross-sectional study. J Community Health. 2022;47(2):211–2. doi:10.1007/s10900-021-01039-3.
- Ministero della Salute. Aggiornamento indicazioni sulla Vaccinazione dei soggetti che hanno avuto un’infezione da SARS-CoV-2. Circolare n° 32884-21/07/2021-DGPRE- DGPRE-P. 2021. 1–4.
- Agenzia Italiana del Farmaco. FAQ Vaccine COVID-19 [accessed 2022 December 11]. https://www.aifa.gov.it/domande-e-risposte-su-vaccini-covid-19
- Centers for Diseases Control and Prevention (CDC). Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States [accessed 2022 Dec 12]. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html
- Traversi D, Pulliero A, Izzotti A, Franchitti E, Iacoviello L, Gianfagna F, Gialluisi A, Izzi B, Agodi A, Barchitta M, et al. Precision medicine and public health: new challenges for effective and sustainable health. J Pers Med. 2021;11(2):135. doi:10.3390/jpm11020135.
- Tamburro M, Ripabelli G, Salzo A, Sammarco ML. Public health, personalized medicine, and COVID-19 in the pre-vaccination phase: a narrative review of the literature on unfavorable prognostic factors in Italian patients. Epidemiol Prev. 2022;46(3):181–91. doi:10.19191/EP22.A450.027.
- Smatti MK, Alkhatib HA, Al Thani AA, Yassine HM. Will host genetics affect the response to SARS-CoV-2 vaccines? Historical precedents. Front Med (Lausanne). 2022;9:802312. doi:10.3389/fmed.2022.802312.